InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（1 笔）
内部人交易记录
首席财务官已披露买入
0
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the detailed record of transactions filed by Biller Jonathan, 首席财务官. Officer active across 4 companies, notably AGIOS PHARMACEUTICALS, INC.. Aggregated, 20 reports have been recorded. Breakdown: 0 buy · 1 sell. Total volume traded: €134k. Activity tracked since 3 December 2021. The latest transaction was filed on 24 February 2026 (Retenue fiscale). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Biller Jonathan
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
1,144 股@ US$485.1116.2% 占其流量Common StockSEC:0000875320-26-000108:0
4,135 股0Common StockSEC:0000875320-26-000084:0
2,993 股@ US$487.7642.3% 占其流量Common StockSEC:0000875320-26-000064:0
1,630 股@ US$468.4122.1% 占其流量Common StockSEC:0000875320-26-000040:0
6,294 股0Common StockSEC:0000875320-26-000014:0
347 股@ US$449.0023.8% 占其流量Common StockSEC:0000875320-25-000240:0
1,259 股@ US$400.00100.0% 占其流量Common StockSEC:0000875320-25-000224:0
1,504 股@ US$463.4627.4% 占其流量Common StockSEC:0000875320-25-000085:0
4,437 股0Common StockSEC:0000875320-25-000063:0
1,632 股@ US$467.9830.5% 占其流量Common StockSEC:0000875320-25-000039:0
4,744 股0Common StockSEC:0000875320-25-000014:0
630 股@ US$466.8410.9% 占其流量Common StockSEC:0000875320-24-000214:0
1,588 股@ US$422.7425.6% 占其流量Common StockSEC:0000875320-24-000047:0
6,294 股0Common StockSEC:0000875320-24-000022:0
408 股@ US$350.725.6% 占其流量Common StockSEC:0001209191-23-051408:0
6,293 股0Common StockSEC:0001209191-23-006913:0
5,294 股0Common StockSEC:0000899243-22-031641:0
8,523 股0Common stockSEC:0001439222-22-000018:0
3,667 股0Common stockSEC:0001439222-22-000006:0
5,753 股0Common stockSEC:0001439222-21-000076:0
20 条申报中的 20 条
About Biller Jonathan
Biller Jonathan is Chief Financial Officer and has 20 filings in total. Across the 20 tracked filings, no purchases are reported, sales total EUR 133991, the most frequent transaction nature is Retenue fiscale, and the observed period runs from 2021-12-07 to 2026-02-26. The recent filings concern Vertex Pharmaceuticals INC / MA and VERTEX PHARMACEUTICALS INC / MA, with amounts including EUR 1230039.093317858 on 2026-02-18, EUR 740663.065011464 on 2025-02-12, EUR 666283.2903718367 on 2025-02-19, EUR 641385.1281320235 on 2026-02-12, EUR 622896.1841565638 on 2024-02-13, and EUR 470555.5399599229 on 2026-02-26.
